Abstract

Background:Improving quality of life (QoL) is one of the key targets when treating systemic lupus erythematosus (SLE) patients. The Lupus impact Tracker (LIT) is a 10-item questionnaire that has demonstrated...

Full Text

Published Version

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
The lupus impact tracker is responsive to changes in clinical activity measured by the systemic lupus erythematosus responder index.
H Devilliers ... M Jolly
Lupus | VOL. 26
H Devilliers, et. al.H Devilliers ... M Jolly
28 Sep 2016
69 Lupus impact tracker can differentiate among treat 2 target outcomes in lupus patients with and without concurrent fibromyalgia
Meenakshi Jolly ...
-
Meenakshi Jolly, et. al.Meenakshi Jolly ...
01 Apr 2019
AB1054 Lupus Impact Tracker is Responsive to Changes in SELENA-SLEDAI in Lupus
H Devilliers ... M Jolly
Annals of the Rheumatic Diseases | VOL. 73
H Devilliers, et. al.H Devilliers ... M Jolly
01 Jun 2014
Validation of the Lupus Impact Tracker in an Australian patient cohort.
A Antony ... M Jolly
Lupus | VOL. 26
A Antony, et. al.A Antony ... M Jolly
20 Aug 2016
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
Expert consensus recommendations for the diagnosis and treatment of chronic non-bacterial osteitis (CNO) in adults
Elizabeth M Winter ... Anne T Leerling
Annals of the Rheumatic Diseases | VOL. -
Elizabeth M Winter, et. al.Elizabeth M Winter ... Anne T Leerling
28 Nov 2024
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
Jinjing Liu ... Xiaofeng Zeng
Annals of the Rheumatic Diseases | VOL. -
Jinjing Liu, et. al.Jinjing Liu ... Xiaofeng Zeng
27 Nov 2024
CD-19 CAR-T cells for polyrefractory rheumatoid arthritis
Merav Lidar ... Abraham Avigdor
Annals of the Rheumatic Diseases | VOL. -
Merav Lidar, et. al.Merav Lidar ... Abraham Avigdor
27 Nov 2024
Correction: Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment
-
Annals of the Rheumatic Diseases | VOL. -
--
27 Nov 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.